223Ra α-Therapy in Patients with Bone Metastases from Castration-resistant Prostate Cancer

Fischer, 2012, Radionuclide therapy of bone metastases, Breast Care (Basel), 7, 100, 10.1159/000337634 Thiery, 2002, Epithelial-mesenchymal transitions in tumour progression, Nat Rev Cancer, 2, 442, 10.1038/nrc822 Ibrahim, 2010, Pathogenesis of osteoblatic bone metastases from prostate cancer, Cancer, 116, 1406, 10.1002/cncr.24896 Morrissey, 2007, The role of tumor microenvironment in prostate cancer bone metastasis, J Cell Biochem, 101, 873, 10.1002/jcb.21214 Logothetis, 2005, Osteoblasts in prostate cancer metastasis to bone, Nat Rev Cancer, 5, 21, 10.1038/nrc1528 deBono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic crastration-resistant prostate cancer progressing after doxetaxel tratement: A randomized open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Danila, 2010, Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer, J Clin Oncol, 28, 1496, 10.1200/JCO.2009.25.9259 Silberstein, 2000, Systematic radiopharmaceutical therapy of painful osteoblastic metastases, Semin Radiat Oncol, 10, 240, 10.1053/srao.2000.6592 Smith, 2009, Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer, J Urol, 182, 2670, 10.1016/j.juro.2009.08.048 Smith, 2009, Denosumab in men receiving androgen- deprivation therapy for prostate cancer, N Engl J Med, 361, 745, 10.1056/NEJMoa0809003 Dauer, 2014, Radiation safety considerations for the use of 223RaCl2 DE in men with castration-resistant prostate cancer, Health Phys, 106, 494, 10.1097/HP.0b013e3182a82b37 Fizazi, 2009, Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer, J Clin Oncol, 27, 2429, 10.1200/JCO.2008.18.9811 Morris, 2009, Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer, J Clin Oncol, 27, 2436, 10.1200/JCO.2008.20.4164 Suttman, 2008, Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: First experience, Cancer Biother Radiopharm, 23, 609, 10.1089/cbr.2008.0487 Zyskowski, 2001, Strontium-89 treatment for prostate cancer bone metastases: Does a prostate specific antigen response predict for improved survival?, Australas Radiol, 45, 39, 10.1046/j.1440-1673.2001.00871.x Pandit-Taskar, 2014, Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: α therapy with 223Ra-dichloride, J Nucl Med, 55, 1, 10.2967/jnumed.112.112482 Sinzinger, 2011, The Vienna protocol and perspective in radionuclide therapy, Q J Nucl Med Mol Imaging, 55, 420 Rubini, 2014, Radiometabolic treatment of bone- metastasizing cancer: From 128Rhenium to 223Radium, Cancer Biother Radiopharm, 29, 1, 10.1089/cbr.2013.1549 Jadvar, 2013, Targeted α-particle therapy of bone metastases in prostate cancer, Clin Nucl Med, 38, 966, 10.1097/RLU.0000000000000290 Hobbs, 2012, A bone marrow toxicity model for Ra-223 alpha-emitter radiopharmaceutical therapy, Phys Med Biol, 57, 3207, 10.1088/0031-9155/57/10/3207 2014 Nilsson, 2012, Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases, Clin Genitourin Cancer, 11, 20, 10.1016/j.clgc.2012.07.002 Nilsson, 2007, Bone-target radium-223 in symptomatic, hormone- refractory prostate cancer: A randomized, multicentre, placebo-controlled phase II study, Lancet Oncol, 8, 587, 10.1016/S1470-2045(07)70147-X Parker, 2013, Overall survival benefit of radium-223 chloride in the treatment of patients with symptomatic bone metastases in castration resistant prostate cancer: A phase III randomized trial (ALSYMPCA), J Clin Oncol, 30 Hindorf, 2012, Quantitative imaging of 223Ra- chloride (Alpharadin) for target alpha-emitting radionuclide therapy of bone metastases, Nucl Med Commun, 33, 726, 10.1097/MNM.0b013e328353bb6e Lassmann, 2013, Dosimetry of 223Ra-chloride: Dose to normal organs and tissues, Eur J Nucl Med Mol Imaging, 40, 207, 10.1007/s00259-012-2265-y Bodei, 2008, EANM procedure guideline for treatment of refractory metastatic bone pain, Eur J Nucl Med Mol Imaging, 35, 1934, 10.1007/s00259-008-0841-y Nilsson, 2005, First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases, Clin Cancer Res, 11, 4451, 10.1158/1078-0432.CCR-04-2244 Carrasquillo, 2013, Phase I pharmacokinetic and biodistribution study with escalating doses of Ra-dichloride in men with castration- resistant metastatic prostate cancer, Eur J Nucl Med Mol Imaging, 40, 1384, 10.1007/s00259-013-2427-6 Vapiwala, 2013, Fighting prostate cancer with radium-223: Not your madame’s isotope, N Engl J Med, 369, 276, 10.1056/NEJMe1304041 Larson RH, Bruland OS. Radium revisited: Targeting of skeletal metastases by the alpha- emitter radium-223. Available from http://www.bruland.info/PDF/195-202.pdf. Accessed August 26, 2014.